J Clin Lipidol. 2013 May-Jun;7(3):217-21. doi: 10.1016/j.jacl.2013.01.005. Epub 2013 Feb 4.
Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum.
Rynkiewicz A, Cybulska B, Banach M, Filipiak K, Guzik T, Idzior-Waluś B, Imiela J, Jankowski P, Kłosiewicz-Latoszek L, Limon J, Myśliwiec M, Opolski G, Steciwko A, Stępińska J, Zdrojewski T.
1st Department of Cardiology, Medical University of Gdansk, Debinki 7; 80-211 Gdansk, Poland.
Heterozygous familial hypercholesterolemia (HFH) affects on average 1 in 500 individuals in European countries, and it is estimated that HeFH in Poland may affect more than 80,000 people. Cardiovascular mortality in individuals with FH between 20 and 39 years of age is 100 times higher than in the general population. HFH is a relatively common lipid disorder, but usually still remaining undiagnosed and untreated. A very high risk of cardiovascular diseases and a shortened lifespan in patients with this condition require early diagnosis and intensive treatment. The aim of the position paper was to present the importance and scale of this problem in Poland, which has not been raised enough so far, as well as the recommendations of diagnosis, treatment and prevention methods.
Copyright © 2013 National Lipid Association. Published by Elsevier Inc. All rights reserved.
- [PubMed - in process]